BICO Group AB Class B (BICO) AI Stock Analysis

• Market Cap: kr1.22B
• Dividend Yield: N/A
• Average Volume (3M): 288.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: -23.24%
• EPS Growth: 45.32%
• Country: SE
• Employees: 695
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -15.71
• Shares Outstanding: 69,074,900
• 10 Day Avg. Volume: 264,488
• 30 Day Avg. Volume: 288,586
• PEG Ratio: 4.13
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 1.16
• P/FCF Ratio: 31.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: kr18.00 ▼(-0.88% Downside)

BICO Group AB Class B's overall stock score is driven by significant financial performance challenges, including declining revenue and negative profit margins. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. While the earnings call provided some positive insights, such as strong growth in Lab Automation, the overall outlook remains cautious due to macroeconomic challenges and operational inefficiencies.

Positive Factors

Lab Automation Growth

The strong growth in Lab Automation indicates robust demand and successful execution of strategic initiatives, enhancing BICO's market position in this segment.

Significant Orders

Large orders from a global pharma company highlight BICO's competitive edge and potential for sustained revenue streams in the lab automation market.

Strengthened Cash Position

The strengthened cash position from divestments provides BICO with greater financial flexibility to invest in growth opportunities and manage operational needs.

Negative Factors

Declining Revenue

Declining revenue growth poses a challenge to BICO's ability to scale operations and maintain competitive advantage in the biotechnology sector.

Negative Profit Margins

Negative profit margins indicate inefficiencies in converting revenue into profit, threatening long-term sustainability and shareholder value.

Negative Cash Flow

Negative cash flow from operations suggests liquidity constraints, potentially limiting BICO's ability to fund growth initiatives and manage financial obligations.

BICO Group AB Class B Business Overview & Revenue Model

Company Description

BICO Group AB Class B (BICO) is a leading company in the biotechnology sector, focusing on innovative solutions in the life sciences and healthcare industries. The company specializes in biofabrication, offering advanced technologies and services for the development of tissue engineering and regenerative medicine. BICO's core products include bioprinters, biomaterials, and related software, which enable researchers and medical professionals to create and manipulate biological structures for research and therapeutic applications.

How the Company Makes Money

BICO generates revenue primarily through the sale of its bioprinting systems, biomaterials, and software solutions. The company has established key revenue streams from direct sales of its products to research institutions, universities, and healthcare providers, as well as recurring revenue from consumables and maintenance services. Additionally, BICO benefits from strategic partnerships with academic institutions and industry players, facilitating collaborations that enhance its product offerings and market reach. The company's focus on innovation and its ability to secure grants and funding for research projects also contribute to its earnings.

BICO Group AB Class B Financial Statement Overview

Summary

BICO Group AB Class B faces significant challenges in profitability and cash flow management, with declining revenue and negative profit margins. While the balance sheet shows moderate leverage, the negative return on equity and declining free cash flow growth highlight operational inefficiencies and liquidity concerns.

Income Statement

BICO Group AB Class B has experienced declining revenue growth, with a negative trend in revenue growth rate over the past periods, including a -6.10% in TTM. The gross profit margin remains relatively strong at 54.11% TTM, but the company is struggling with profitability as evidenced by negative net profit margins and EBIT margins. The net profit margin is particularly concerning at -10.62% TTM, indicating significant challenges in converting revenue into profit.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.53 TTM, which suggests a manageable level of leverage. However, the return on equity is negative at -7.46% TTM, indicating inefficiencies in generating returns for shareholders. The equity ratio is not explicitly calculated, but the company maintains a reasonable level of equity relative to its assets.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth at -30.13% TTM, which is a concern for future liquidity. The operating cash flow to net income ratio is 0.16 TTM, suggesting some ability to cover net income with operating cash flow, but the overall cash flow situation is strained, as indicated by the negative free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.67B	1.95B	2.01B	2.24B	1.26B	176.79M
Gross Profit	846.10M	1.01B	993.20M	1.83B	1.00B	163.62M
EBITDA	-686.70M	505.30M	442.80M	322.30M	31.80M	-39.50M
Net Income	-682.90M	-5.50M	-1.17B	-835.70M	-229.20M	-61.89M
Balance Sheet
Total Assets	3.74B	5.48B	6.06B	10.20B	9.75B	1.65B
Cash, Cash Equivalents and Short-Term Investments	1.24B	598.00M	804.10M	925.20M	1.48B	995.80M
Total Debt	1.30B	1.76B	1.96B	1.85B	1.61B	62.49M
Total Liabilities	1.93B	2.48B	2.96B	3.26B	2.95B	126.74M
Stockholders Equity	1.81B	2.98B	3.07B	6.91B	6.77B	1.52B
Cash Flow
Free Cash Flow	164.40M	72.70M	-112.80M	-799.00M	-676.20M	-154.12M
Operating Cash Flow	198.50M	158.40M	178.40M	-269.40M	-409.20M	-71.82M
Investing Cash Flow	928.00M	128.00M	-129.70M	212.90M	-4.45B	-200.90M
Financing Cash Flow	-574.70M	-200.70M	-102.00M	455.30M	4.90B	1.04B

BICO Group AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BICO, the sentiment is Negative. The current price of 18.16 is below the 20-day moving average (MA) of 18.62, below the 50-day MA of 18.87, and below the 200-day MA of 27.34, indicating a bearish trend. The MACD of -0.47 indicates Positive momentum. The RSI at 38.95 is Neutral, neither overbought nor oversold. The STOCH value of 46.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BICO.

BICO Group AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	71 Outperform	kr3.52B	23.22	17.89%	1.61%	1.53%	0.79%
CRAD.B	66 Neutral	kr1.07B	45.72	6.93%	―	-5.80%	-65.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BICO	50 Neutral	kr1.22B	-1.78	-57.26%	―	-23.24%	45.32%
SEDANA	48 Neutral	kr997.34M	-24.54	-4.42%	―	13.48%	28.98%
BACTI.B	46 Neutral	kr606.26M	-28.50	-6.81%	―	-8.10%	62.08%
SEZI	43 Neutral	kr786.08M	-5.77	-36.55%	―	62.24%	21.16%

BICO Group AB Class B Corporate Events

BICO Group Appoints New Chief Operations & Digital Officer

BICO Group AB has appointed Jesper Hagberg as the new Chief Operations & Digital Officer, effective January 7, 2026. Hagberg, who has over 25 years of experience in digital transformation and operational excellence, is expected to contribute significantly to BICO’s growth and innovation. His appointment is seen as a strategic move to enhance the company’s operations and digital capabilities, further solidifying BICO’s position in the lab automation and life science solutions industry.

The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK20.50 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.

BICO Group Appoints Ewa Linsäter as New CFO

BICO Group AB has announced the appointment of Ewa Linsäter as the new Chief Financial Officer, succeeding Jacob Thordenberg. Linsäter brings over 15 years of experience in financial leadership roles, including her recent position at Elos Medtech. Her expertise in international life science and mergers and acquisitions is expected to contribute significantly to BICO’s strategic ambitions in lab automation and life science solutions. This leadership transition is poised to strengthen BICO’s financial position and support its continued development in the industry.

The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK20.50 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.

BICO Group AB Reports Q3 2025 Financial Results with Mixed Performance

BICO Group AB’s interim report for Q3 2025 shows a 4.8% increase in net sales compared to the previous year, with significant growth in lab automation and life science solutions. Despite these gains, the company faced challenges with impairments in Discover ECHO and Biosero, impacting EBIT, but divestments of MatTek and Visikol strengthened their cash position.

The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.

BICO Group AB Reports Q3 Growth Amid Impairments

BICO Group AB reported preliminary figures for Q3 2025, highlighting an organic sales growth of 12% and an improved adjusted EBITDA margin. However, the company announced significant impairments totaling SEK 1,036m due to revised forecast assumptions and weaker financial performance in certain segments, impacting EBIT but not cash flow. Despite these challenges, BICO anticipates long-term growth and reaffirms strong demand for its lab automation solutions.

The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.

BICO Group AB to Release Q3 2025 Interim Report

BICO Group AB announced the release of its Q3 2025 interim report scheduled for November 4, 2025. Following the report’s publication, a telephone conference will be held to discuss the results, featuring presentations by the company’s President & CEO and CFO. This announcement reflects BICO’s commitment to transparency and engagement with stakeholders, providing insights into its financial performance and strategic direction.

The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.